31^st International Conference on Cardiology and Cardiovascular Diseases August 07-08, 2023 Amsterdam, Netherlands

Dr. Burton M. Altura is currently working as a Professor of Physiology, Pharmacology & Medicine State University of New York Downstate Medical Center. He completed his PhD from Newyork University School of Medicine. He published many articles. Dr. Burton M. Altura studies address the two most important issues in vascular biology today: stroke mechanisms; and irreversible cellular destruction in the cardiovascular system caused by alcohol and substance abuse. These studies have already led to the prevention of atherosclerotic lesions, hypertension and stroke-like events in experimental animal models.

Physiology Vagal Maneuvers Pharmacology Medicine

Dr. Yeung is currently Professor of Pharmacy and Medicine in Dalhousie University (Halifax, NS, Canada). He is an active contributor and consultant for many academic and professional organizations, pharmaceutical industry, granting councils and the Government. He is currently a member on the Board of the Canadian Society of Pharmaceutical Sciences (CSPS), a member on the Editorial Board for Recent Review of Clinical Trials, Drug Metabolism Open Journal, Metabolites and Medical Sciences Monitor. He was the Vice Chair of the Cardiovascular, Pulmonary and Renal (CPR) Section of American Society of Clinical Pharmacology and Therapeutics (ASCPT) from 2006 -2010, a member of the Board of Biotechnology Life Sciences Industry Association in Nova Scotia (BioNova) from 1999 – 2007, Scientific Officer for Nova Scotia Health Research Foundation from 2009 -2011, Member of the Scientific Advisory Committee on Oncology Therapies for Health Canada from 2004 – 2007.

Pharmacokinetics, Metabolism and Biomarker assessment or Cardiovascular and Anti-cancer drugs.

I am an academic cardiologist with a wide range of interest in clinical cardiology. Over the last 20 years I have focussed my research in coronary artery disease particularly the ECG changes of acute STEMI. Modern technologies such as smart phones with dedicated apps, etc allow these ECG signals to be captured, transmitted, centralized, and analysed. Their utility is incremental with newer technology, but the findings from ECG studies always form the scientific backbone for any clinical application. My current aim is to help refine the electrocardiographic language of STEMIs. I have published over 150 journal articles / book chapters.

Coronary artery disease

Dr. Ellahham is a Board-certified internist, cardiologist and vascular medicine senior consultant and continues to care for patients. He received his undergraduate degree in biology and his M.D. from the American University of Beirut, Beirut, Lebanon. Dr. Ellahham did his fellowship in Cardiology at the Medical College of Virginia (MCV) in USA. After completing his fellowship, Dr. Ellahham worked in Washington DC in several clinical and leadership positions before moving to UAE in 2008. He is board certified in internal medicine, vascular medicine, cardiology and quality. He is a fellow of the American College of Cardiology and key member in Heart Failure and Transplant, Adult Congenital and Pediatric Cardiology, Cardio-oncology and Peripheral Vascular Disease Sections. He is currently Cleveland Clinic Staff and caregiver seconded in Abu Dhabi, UAE. Dr. Ellahham is a fellow of the American College of Chest Physicians, American College of Physicians, and American Heart Association.

Dr. Ellahham is an avid researcher; his research includes heart failure, digital healthcare solutions, telemedicine, block chain, antiplatelet and anticoagulant therapy, and ischemic heart disease. He is also a reviewer for several peer-reviewed journals

Fabio Angeli holds an M.D. degree and works as a Cardiologist and Biomedical Researcher in the Teaching Hospital "S.M. della Misericordia" of Perugia, Italy. He is an investigator and co-responsible for planning and management of mono-center and multi-center clinical studies on cardiovascular drugs (in connection with hospitals and universities), in addition to medical writing. His main areas of interest include cardiovascular risk assessment in patients with hypertension, diabetes, heart failure, acute coronary syndrome and coronary artery disease using electrocardiography, echocardiography, ambulatory blood pressure monitoring, and other noninvasive tests, as well as evaluation of cardiovascular treatment. Dr. Angeli is the author of scientific works on cardiovascular disease, acute coronary syndrome, diabetes, and hypertension (including original articles, meta-analyses, reviews, commentaries) published in leading journals including The Lancet, Circulation, Diabetes Care, JACC, Hypertension, J Hypertens, and others. He has participated to several invited lectures and served as a reviewer for leading medical journals and graders for scientific meetings. Dr. Angeli served also as a member of scientific secretary of several ongoing multicenter studies. His biography was included in Who’sWho in Medicine and Healthcare and Who’sWho in Science and Engineering. He is a “Scientific Fellow” of the “Associazione Nazionale Medici Cardiologi Ospedaliari (A.N.M.C.O.)”.

His main areas of interest include cardiovascular risk assessment in patients with hypertension, diabetes, heart failure, acute coronary syndrome and coronary artery disease using electrocardiography, echocardiography, ambulatory blood pressures monitoring, and other noninvasive tests, as well as evaluation of cardiovascular treatment.

I started my early career in Italy (1979) under the mentorship of Prof. Fulvio Camerini, past Chair of the European Society of Cardiology Nucleus on Myocardial and Pericardial Disease at the University Hospital of Trieste. In 1989, at the University of Utah with Dr. Michael Bristow, I started a molecular genetics approach to myocardial disease. From 1991 to 1998, I worked at the International Centre for Genetic Engineering and Biotechnology (United Nations), where I expanded my research on molecular genetics of cardiomyopathy. In 1998, I joined the University of Colorado, to lead a new program of clinical and molecular genetics. The program is now well established, it includes both clinical care and basic science, and it has trained a number of graduate and post-graduate students.My cardiovascular research has focused on the discovery of Mendelian genes causing dilated cardiomyopathy and other more rare forms of heart muscle disease. My laboratory has discovered several genes and gene mutations and studied the association with the phenotype to provide tools in the clinical setting for diagnosis and therapy. I found that several pathways may be involved, ranging from mechanics of cytoskeleton, to force production, energy production, storage, ion homeostasis and signalling. More recently, I have expanded my research interests toward rare genetic forms of cardiomyopathies, advanced genome and nano science to investigate heart disease with novel tools. I am member of the AHA Pacific Mountain Research Committee since 2007, I served in several review boards of the NIH and AHA and I have recently participated in the expert panel for the development of the AHA guidelines for genetic testing in cardiomyopathies.

Dilated Cardiomyopathy, Arrhythmogenic right Ventricular Dysplasia, Left ventricular noncompaction and Hypertrophic Cardiomyopathy

Dr. Hui Zhang completed her M.D. and Ph.D at China Medical University, Shenyang, China in 2003 and 2011, respectively. She worked as a pediatrician in Shengjing Affiliated Hospital of China Medical University during 2003-2012. She finished his postdoctoral training in Cardiovascular Pulmonary Research, School of Medicine, University of Colorado under the guidance of Dr. Kurt Stenmark in 2015. Since then, she has been promoted to the position of Instructor, Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

My research interests focus on the molecular and cellular mechanisms of the cardiovascular remodeling of pulmonary hypertension (PH) to develop new therapeutic strategies to treat PH. I am also interested in the research of lung injury and lung fibrosis.

Dr. Catherine Demers graduated from Université de Sherbrooke and completed her training in Adult Cardiology at the Montreal Heart Institute. She is currently an Associate Professor in the Department of Medicine, Division of Cardiology. Dr. Demers is involved in the ongoing management of complex heart failure patients at the Heart Function Clinic at the Hamilton Health Sciences.

Research interests include heart failure management in primary care and the impact of cognitive function on self-care and clinical outcomes in older heart failure patients

Dr. Dipak K. Dube is a Professor in the Department of Medicine and an Adjunct Professor in the Department of Cell & Developmental Biology, SUNY Upstate Medical University. He received his Ph.D and D.Sc degrees from University of Calcutta, India. He did his postdoctoral research at the Institute for Cancer Research, Philadelphia, USA. He has published about 150 full-length papers. Dr. Dube is an Associate Editor of Cardiovascular Toxicology. Also, he is a member of Editorial Board of Journal of Cytology & Histology; Clinical and Experimental Cardiology, and Scientifica (Biochemistry).

His major areas of research interests are Molecular Biology of Vertebrate Heart Development and Human Retrovirology.

Dr.Smriti.M.Krishna has received PhD from Division of Cancer Research in 2006.Currently, she is working as Team Leader in The Queensland Research Centre for Peripheral Vascular Disease,James Cook University.She has assisted Teaching classes & Wet Lab teaching classes for MBBS students at Faculty of Medicine & Health Sciences, UAE University, UAE.And she conducted seminars for MBBS & MSc. Students at Regional Cancer Centre, India and classes for Endocrinology during M.Phil. at Dept of Zoology, University of Kerala, India.Currently organising Observership Programs for high school students from Townsville based schools and JCU MBBS students to increase awareness in ongoing research activities and to increase the amount of community interaction with the unit. St. Margaret Marys College, Aitkinvale//Ignatius Park College.She received VBU DBA fund for Oral Presentation in International Society of Cardiovascular Pharmacotherapy (ISCP) & AVBS Conference, Adelaide, 2014.Received grants during 2010–2014 with a total amount of $195,295.She has total 29 publications in reputed Journals.

Atherosclerosis,Cancer Biotherapy & Radiopharmaceuticals,Molecular Biology Reports, Human Immunology,Applied Biochemistry and Biotechnology,Cell Biochemistry & Function.

Prof. Shahzad is currently affiliated with University of Vienna, Austria. Prof. Shahzad is one of the pioneers, working for the progress of translational medicine field. He is serving as a secretary general and director of administration for “international society for translational medicine (ISTM)” He is serving as visiting professor of translational medicine, at the First Affiliated Hospital, Harbin Medical University, Harbin, China. He is also appointed as associate professor of translational medicine (Adj), at the First Affiliated Hospital, Wenzhou Medical College, China. Prof. Shahzad has won many prestigious international fellowships and awards. Prof. Shahzad is invited speaker for many international life sciences conferences.

Translational Research and Clinical Diagnostics

Xiongwen Chen (also known as Wen Chen) is an assistant professor in Cardiovascular Research Center at Temple University. He obtained his BS and MS in Animal Physiology and Biochemistry from China Agricultural University and PhD in Physiology from Temple University. Trained by Dr. Steven R. Houser, a world renowned cardio biologist, Dr. Chen has been studying the underlying molecular and cellular mechanisms for heart failure and exploring potential novel therapy for treating this deadly syndrome. Dr. Chen has published 36 peer-reviewed papers and 4 book chapters in heart failure research field.  

As a NIH and AHA funded investigator, his discoveries of the new aspects of calcium signaling and the beta-adrenergic signaling in heart failure have deepened our understanding of heart failure and provided potential targets for heart failure prevention and treatment. He also explored the idea that there are new myocytes forming from resident cardiac stem cells in adolescent hearts.